Literature DB >> 6625960

Double-blind evaluation of plasmapheresis in schizophrenic patients: a pilot study.

S C Schulz, D P van Kammen, R Waters, H G Klein, J E Balow, W E Bunney.   

Abstract

Interest in the effects and possible mechanisms of hemodialysis on schizophrenic patients has led to a double-blind evaluation of the effects of plasmapheresis on symptoms of schizophrenia. Also, plasmapheresis was felt to be an invaluable tool for investigating the autoimmune theory of schizophrenia. Patients (n = 10) in the study fulfilled Research Diagnostic Criteria for schizophrenia and were randomly assigned to either sham or active plasmapheresis. They were blindly assessed by staff psychiatrists and nurses. Evaluation of the behavioral ratings revealed no significant decrease in psychosis for either the active or sham group. Also, no individual responding patient was identified. This finding complements our group's early negative results of a hemodialysis experiment and casts doubt on a simple autoimmune hypothesis of schizophrenia.

Entities:  

Mesh:

Year:  1983        PMID: 6625960     DOI: 10.1111/j.1525-1594.1983.tb04203.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  3 in total

1.  Facilins, a novel class of biological factors that facilitate the aortic response to dopamine and other biogenic amines.

Authors:  B Silvestrini; M Palmery; L Tolu; F Basta; M G Leone; C Y Cheng
Journal:  J Neural Transm Gen Sect       Date:  1994

2.  Skewing of the antibody repertoire in cerebrospinal fluid B cells from healthy controls and patients with schizophrenia.

Authors:  Sehba Husain-Krautter; Jihui Lee; Duncan Vos; Juan A Gallego; Anil K Malhotra; Thomas L Rothstein
Journal:  Behav Brain Res       Date:  2022-01-07       Impact factor: 3.352

Review 3.  Autoimmune phenotypes in schizophrenia reveal novel treatment targets.

Authors:  Emily G Severance; Faith B Dickerson; Robert H Yolken
Journal:  Pharmacol Ther       Date:  2018-05-06       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.